The opposite activity of ERRα in PCa versus breast cancer on bone resorbing-cells may explain the differences in tumor progression in bone between breast and prostate cancers [22] and suggests distinct clinical management of prostate versus breast cancer patients with bone metastases. This evidence concerns the gene ESRRA and neoplasm.